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lated donors, supported by multiple publications, including
large numbers of transplantation patients, is that matching
for human leukocyte antigen (HLA) is critical to ensure the
best outcomes for patients. The current gold standard is an
unrelated donor matched for 10/10 (or 8/8) HLA alleles (at
HLA-A, -B, -C, -DRB1 þ/ DQB1). Graft-versus-host disease
(GVHD) is increased in the HLA-mismatched setting, and
overall survival becomes signiﬁcantlyworse as the number of
mismatched alleles at these loci increases [1,2].
Interestingly, data now suggest that an HLA mismatch may
actually be tolerated, or even beneﬁcial, in some transplant
settings. This has been shown inparticular forHLA-DPB1where
mismatching for this locus at allelic level reduces the risk of
disease relapse, both inaTcelledepleted [3]andaTcellereplete
setting [4]. Even more provocative is the observation, based on
functional studies, that beingmatched ormismatched for DPB1
T cell epitope (TCE) groups provides a better prediction of
transplant outcomes, including overall survival, than does
consideration of DPB1 allele level matching alone [5].
It is well demonstrated in both the in vivo and in vitro
setting that HLA-DPB1 is able to elicit an allogeneic response
in a speciﬁc manner. This was originally shown in the setting
of GVHD [6] but has since also been shown in the setting of
graft rejection (using the TCE model) [7]. Proof of principle
that HLA-DPB1 mismatches could be a speciﬁc target of the
graft-versus-leukemia (GVL) effect was shown by Ibisch
et al., who demonstrated that primary leukemia blasts both
expressed variable levels of DPB1 on the cells surface and
could be killed by DPB1-speciﬁc T cells [8]. Taking this work
into the clinic, Dr. Falkenburg’s group [9] previously showed
they could detect polyclonal HLA-DPB1 speciﬁc T cells in
a patient with B-cell chronic lymphocytic leukaemia who
responded to donor lymphocyte infusion (DLI) (from a DPB1-
mismatched donor) [9].
In this issue, Rutten and colleagues extend these ﬁndings in
24 patients undergoing transplantation from a 10/10 HLA-
matched, DPB1-mismatched unrelated donor [10]. The
authors develop an elegant assay for quantifying HLA-
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by genetically engineered HeLa stimulator cells. Using this
assay, they monitor peripheral blood samples for the emer-
gence of post-DLI patient HLA-DPespeciﬁc CD4þ T cells. They
report that in over 50% of patients who received HLA-
DPB1emismatchedDLI,DPB1-speciﬁc Tcell responses couldbe
demonstrated. In addition, they show that speciﬁc T cells were
found in a signiﬁcantly higher proportion of patients who had
aclinical response toDLI (72%) than in thosewithouta response
(17%). Although T cell responses were seen predominantly in
patients who developed GVHD (with or without a clinical
response), they present the intriguing ﬁnding that in a propor-
tion of patients with HLA-DPB1especiﬁc T cell responses,
clinical responseswere seenwithout co-existing clinical GVHD.
HLA-DPB1 is indeed an attractive GVL target to exploit in
the unrelated donor setting. In view of frequent recombi-
nation events in this area of the chromosome, DPB1 allele
mismatches are found in>80% of unrelated donor pairs (who
still ﬁt the criteria for being a gold standard donor). However,
it is clear that DPB1 mismatches can result in signiﬁcant
GVHD, potentially limiting its role in immunotherapy. The
ability to separate “good” from “bad” mismatches would be
a signiﬁcant step forward. Some progress in this area has
been made, by applying the DPB1 TCE mismatch model. In
the clinical setting, this has allowed us to predict which DPB1
TCE mismatches (nonpermissive) result in signiﬁcantly more
GVHD and thus should be avoided. Interestingly, however,
nonpermissive mismatches have not been seen to signiﬁ-
cantly reduce disease relapse in the same patient group [5].
Although in the current study, the authors found no signiﬁ-
cant difference in the percentage of DPB1-speciﬁc Tcells seen
between permissive and nonpermissive mismatches, no data
on the association of permissive/nonpermissive mismatches
with GVHD or response to DLI are given. Clearly, more work
in this area would be welcomed.
Another unsolved issue, as highlighted in this study, is
why some patients without a speciﬁc T cell response to an
HLA-DPB1 mismatch nevertheless have a clinical response.
One explanation may be that the T cell responses are below
the threshold of detection or that the sample collection
missed the peak of the response; however, it must be at least
as likely that other genetic factors (eg, minor histocompati-
bility antigens) [11] or combinations of genetic/immuno-
logical factors are responsible for the clinical effect rather
than, or in addition to, the HLA-DPB1 mismatch.
As the authors conclude, the interplay between GVL and
GVHD is likely to be complex and mediated by genetic and
other factors that may differ in speciﬁc individuals. Studies
such as this one move us toward a better understanding of
these factors. It is hoped that future studies, particularly
prospective and randomized, can shed further light on these
important questions.
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Liga and collaborators reported on low doses of donor
lymphocytes given after Tcelledepleted transplants for acute
leukemia [1]. Patients received lymphocytes if they had
evidence of mixed chimerism after transplant or if disease
was deemed to be at high risk of relapse. Ultimately, 15 of 56
patients undergoing transplantation received prophylactic
donor lymphocytes, which induced full donor chimerism in
75%of the cases.Despite amedian infused cell doseof only2
106 CD3/kg (given at a median of 162 days after transplant),
the donor lymphocyte infusion (DLI)-related mortality was
estimated at 27% (4 graft-versus-host disease [GVHD]-related
deaths). No recurrences were seen among the remaining 11
recipients of prophylactic lymphocytes.
This study illustrates the complexities, successes, and
limitations of our current understanding (or lack thereof) of
post-transplantation relapse biology, prevention, and treat-
ment. Relapse occurs in approximately 40% of patients and
remains the most common cause of death after trans-
plantation; the prognosis of patients with most hematologic
malignancies that relapse after allogeneic transplants isunfortunately very guarded [2]. DLIs have been used most
frequently in the context of relapse but with varied results
and signiﬁcant treatment-related mortality, due to GVHD
and infections. Depleting the graft of alloreactive T cells
(in vivo or ex vivo) has led to remarkably low GVHD rates,
with varying results in terms of relapse, infections, compli-
cations, and primary disease relapse. T cell “add back,” as
proposed by Liga et al., may, to some extent, defy the original
proposition of graft T cell depletion, in that it is often
complicated by the same problems (ie, GVHD) the T cell
depletion intended to avoid. Delaying the infusion does
decrease the likelihood of GVHD but, as demonstrated here,
does not abolish the risk. The strategy of delaying the DLI
used to prevent relapse also is not devoid of risks: A signif-
icant fraction of acute leukemia relapses after allogeneic
transplants occurs during the ﬁrst 6 months. In the report of
Liga et al. patients that received the prophylactic lympho-
cytes, however, did not relapse.
Review of the literature of planned DLIs illustrates the
variability in approaches. Median cumulative cell doses
ranges from 0.2  106 to 70  106 T cells/kg, with a highly
variable schedule of infusions [2]. In addition to prophylactic
DLIs, multiple methods have been proposed over the years to
minimize the likelihood of recurrence, ranging from
intensiﬁed preparative regimens to newer cell therapy or
vaccination approaches designed to increase the graft-
versus-leukemia effect without GVHD [3-6]. When
analyzed disregarding single-center reports, relapse rates for
high-risk patients have not changed much since Dr. Thomas’
initial publications in the 1970s and 1980s, unfortunately.
The same considerations of lack of consensus and absence of
uniformly effective treatments characterize the scenario of
relapse treatment as well.
